- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Hester Biosciences Limited — Updates, 30-01-2026: Press Release
30-01-2026 | 11:38 am
30-01-2026 | 11:38 am
HesterBio reports strong Q3 standalone profit surge (+140% PAT to ₹10.67 Cr) on 12% revenue growth (₹70.35 Cr). Consolidated revenue +22% (₹77.41 Cr) but PAT -18%. CEO re-appointed. New H9N2 vaccine license and doubled capacity position for growth. Animal Healthcare order delays expected to clear in Q4.
No comments yet. Be the first to comment!